These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 35757014)

  • 1. Synergistic Antitumor Effects of Anlotinib Combined with Oral 5-Fluorouracil/S-1 via Inhibiting Src/AKT Signaling Pathway in Small-Cell Lung Cancer.
    Xia X; Pi W; Lan Y; Wu X; Lv D; Meng Y; Yang H; Wang W
    Anal Cell Pathol (Amst); 2022; 2022():4484211. PubMed ID: 35757014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anlotinib Inhibits Cell Proliferation, Migration and Invasion via Suppression of c-Met Pathway and Activation of ERK1/2 Pathway in H446 Cells.
    Tang X; Zheng Y; Jiao D; Chen J; Liu X; Xiong S; Chen Q
    Anticancer Agents Med Chem; 2021; 21(6):747-755. PubMed ID: 32682383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel multi-target tyrosine kinase inhibitor anlotinib combined with irinotecan has in-vitro anti-tumor activity against human small-cell lung cancer.
    Li H; Liu Y; Liu X; Zhao D; Liu J; Cheng Y
    Anticancer Drugs; 2020 Nov; 31(10):1057-1064. PubMed ID: 32694423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway.
    Lan W; Zhao J; Chen W; Shang H; Peng J; Lin J
    Anticancer Agents Med Chem; 2021; 21(15):1987-1995. PubMed ID: 33438566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anlotinib may enhance the efficacy of anti-PD1 therapy by inhibiting the AKT pathway and promoting the apoptosis of CAFs in lung adenocarcinoma.
    Tang H; You T; Ge H; Gao J; Wang Y; Bai C; Sun Z; Han Q; Zhao RC
    Int Immunopharmacol; 2024 May; 133():112053. PubMed ID: 38615380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.
    Song F; Hu B; Cheng JW; Sun YF; Zhou KQ; Wang PX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
    Cell Death Dis; 2020 Jul; 11(7):573. PubMed ID: 32709873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulating IL-6/GP130 targets improved the anti-tumor effects of 5-fluorouracil in colon cancer.
    Li S; Tian J; Zhang H; Zhou S; Wang X; Zhang L; Yang J; Zhang Z; Ji Z
    Apoptosis; 2018 Jun; 23(5-6):356-374. PubMed ID: 29777330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extract of
    Cui XL; Li KJ; Ren HX; Zhang YJ; Liu XD; Bu BG; Wang L
    World J Gastroenterol; 2019 Apr; 25(15):1854-1864. PubMed ID: 31057299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydrazinocurcumin and 5-fluorouracil enhance apoptosis and restrain tumorigenicity of HepG2 cells via disrupting the PTEN-mediated PI3K/Akt signaling pathway.
    Zhou Y; Zhang M; Zhang Z; Jia Y; Zhang C; Peng L
    Biomed Pharmacother; 2020 Sep; 129():109851. PubMed ID: 32559627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melatonin synergizes the chemotherapeutic effect of 5-fluorouracil in colon cancer by suppressing PI3K/AKT and NF-κB/iNOS signaling pathways.
    Gao Y; Xiao X; Zhang C; Yu W; Guo W; Zhang Z; Li Z; Feng X; Hao J; Zhang K; Xiao B; Chen M; Huang W; Xiong S; Wu X; Deng W
    J Pineal Res; 2017 Mar; 62(2):. PubMed ID: 27865009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects and Mechanisms of Anlotinib and Dihydroartemisinin Combination Therapy in Ameliorating Malignant Biological Behavior of Gastric Cancer Cells.
    Luo Q; Zhang S; Zhang D; Feng R; Li N; Chen W; Chen X; Yang S
    Curr Pharm Biotechnol; 2021; 22(4):523-533. PubMed ID: 32576126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anlotinib induces hepatocellular carcinoma apoptosis and inhibits proliferation via Erk and Akt pathway.
    He C; Wu T; Hao Y
    Biochem Biophys Res Commun; 2018 Sep; 503(4):3093-3099. PubMed ID: 30146257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells.
    Liang L; Hui K; Hu C; Wen Y; Yang S; Zhu P; Wang L; Xia Y; Qiao Y; Sun W; Fei J; Chen T; Zhao F; Yang B; Jiang X
    J Exp Clin Cancer Res; 2019 Feb; 38(1):71. PubMed ID: 30755242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anlotinib Combined with S-1 in the Third-Line Treatment of Stage IV Non-Small Cell Lung Cancer: Study Protocol for Phase II Clinical Trial.
    Yang X; Xiang M; Geng L; Wen Y; Du X
    Asian Pac J Cancer Prev; 2019 Dec; 20(12):3849-3853. PubMed ID: 31870132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppressed mitochondrial respiration via NOX5-mediated redox imbalance contributes to the antitumor activity of anlotinib in oral squamous cell carcinoma.
    Huang Z; Su Q; Li W; Ren H; Huang H; Wang A
    J Genet Genomics; 2021 Jul; 48(7):582-594. PubMed ID: 34373220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Traditional Chinese Medicine Brucea Javanica Oil Enhances the Efficacy of Anlotinib in a Mouse Model of Liver-Metastasis of Small-cell Lung Cancer.
    Peng S; Dong W; Chu Q; Meng J; Yang H; DU Y; Sun YU; Hoffman RM
    In Vivo; 2021; 35(3):1437-1441. PubMed ID: 33910820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
    Chen Q; Li Y; Zhang W; Wang C; Yang S; Guo Q
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):401-408. PubMed ID: 34797416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI3K inhibitor impairs tumor progression and enhances sensitivity to anlotinib in anlotinib-resistant osteosarcoma.
    Chen C; Guo Y; Huang Q; Wang B; Wang W; Niu J; Lou J; Xu J; Ren T; Huang Y; Guo W
    Cancer Lett; 2022 Jun; 536():215660. PubMed ID: 35318116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib.
    Chen D; Xu J; Zhao Y; Chu T; Zhong H; Han B; Zhong R
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):401-406. PubMed ID: 31691871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Curcumin synergizes with 5-fluorouracil by impairing AMPK/ULK1-dependent autophagy, AKT activity and enhancing apoptosis in colon cancer cells with tumor growth inhibition in xenograft mice.
    Zhang P; Lai ZL; Chen HF; Zhang M; Wang A; Jia T; Sun WQ; Zhu XM; Chen XF; Zhao Z; Zhang J
    J Exp Clin Cancer Res; 2017 Dec; 36(1):190. PubMed ID: 29273065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.